RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo

Nidhi Jyotsana1, Amit Sharma1, Anuhar Chaturvedi1, Michaela Scherr1, Florian Kuchenbauer2, Laszlo Sajti3, Annette Barchanski3, Robert Lindner4, Fatih Noyan5, Kurt-Wolfram Sühs6, Denis Grote-Koska7, Korbinian Brand7, Hans-Peter Vornlocher8, Martin Stanulla9, Beat Bornhauser10, Jean-Pierre Bourquin10, Matthias Eder1, Felicitas Thol1, Arnold Ganser1, R. Keith Humphries11,12, Euan Ramsay13, Pieter Cullis14, and Michael Heuser1

1Dept. of Hematology, Hemostasis, Oncology and Stem cell Transplantation, Hannover Medical School, Hannover, Germany 2Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany 3Nanotechnology Department, Laser Zentrum Hannover, 30419, Hannover, Germany 4Dept. of Cell Biology, Center of Anatomy, Hannover Medical School, Germany 5Dept. of Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, Germany 6Clinic for Neurology, Hannover Medical School, Hannover, Germany 7Dept. of Clinical Chemistry, Hannover Medical School, Hannover, Germany 8Axolabs GmBH, Kulmbach, Germany 9Pediatric Hematology and Oncology, Hannover Medical School, Germany 10Department of Oncology and Children's Research Centre, University Children's Hospital Zürich, 8032 Zürich, Switzerland 11Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada 12Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada 13Precision NanoSystems Inc, Vancouver, BC, Canada 14Department of Biochemistry and Molecular Biology, University of British Columbia, 2350 Health Sciences Mall, Vancouver, British Columbia, Canada, V6T 1Z3

Despite the wide therapeutic potential of RNA interference (RNAi), clinical progress has been slow with only a few examples of successful translation. Efficient knockdown of hepatic transthyretin (87%) in patients with transthyretin amyloidosis lasted for several weeks after a single dose.1 Also, in a phase I clinical trial, a single dose of inclisiran (siRNA against the PCSK9 mRNA) efficiently suppressed serum cholesterol for 6 months.2 However, these studies suggested that siRNA delivery beyond the liver is not yet feasible in the clinic and thus limits the potential benefit of RNAi. Lipid nanoparticles (LNPs) containing ionizable cationic lipids embody the most advanced delivery platform for systemic administration of RNAi therapeutics.3 Our study provides a preclinical proof-of-
concept that RNAi therapeutics can be exploited against leukemia cells using LNPs as a delivery tool, in a patient derived B cell acute lymphoblastic leukemia (ALL) xenograft mouse model.

Chromosomal translocations are considered driver mutations in leukemogenesis, and are usually present in all leukemic cells and are retained during relapse. 4 75% of pediatric ALL patients harbour gross chromosomal aberrations, with ETV6-RUNX1, TCF3-PBX1, MLL rearrangements and BCR-ABL1 being the most relevant mutations. 5 Continuous efforts have been made to target fusion oncogenes by delivering siRNAs in vitro such as anti-BCR-ABL siRNA in K562 cells, 6 and anti-MLL-AF9 siRNA in THP1 cells, 7 and in vivo such as anti-SS18-SSX1 siRNA in a synovial sarcoma xenograft model, 8 and anti-TMPRSS2-ERG siRNA in a prostate cancer xenograft model. 9 Anti-BCR-ABL siRNA was also administered intravenously in an imatinib resistant chronic myeloid leukemia (CML) patient and showed efficient knockdown of the BCR-ABL fusion gene and good tolerability. 10

The translocation t(1;19)(q23;p13), resulting in the fusion gene TCF3-PBX1 (also called E2A/PBX1), is one of the most frequent translocations in B-ALL in both adult and pediatric populations at an overall frequency of 5-10%. 11 Despite of intensive chemotherapy approximately 10% of TCF3-PBX1 positive patients experience relapse with dismal prognosis, and novel treatment approaches are urgently needed for these patients. 12

To improve delivery of siRNAs to non-hepatic tissues, especially to leukemic cells in bone marrow, spleen and blood, we developed proprietary lipid nanoparticles (LNP, SUB9KITS, see Supplemental Methods) and a microfluidics device (NanoAssemblr™) to reproducibly encapsulate siRNA in LNPs (Supplemental Figure S1A). LNP-siRNA intracellular uptake and efficacy were evaluated in vitro in TCF3-PBX1 expressing 697 cells (DSMZ, Braunschweig, Germany) and in vivo in a patient derived xenograft (PDX) model from a TCF3-PBX1 positive ALL patient. 13 Packaged LNPs were analyzed for size and charge characteristics with the zetasizer instrument (Malvern Instruments, Herrenberg, Germany). The estimated mean diameter of our LNP-siRNA formulations (lipid/siRNA weight ratio 10:1) was 55 nm (Supplemental Figure S1B). We reproducibly encapsulated more than 90% of the used siRNA inside the LNPs (Supplemental Figure S1C).

The efficacy of four manually designed siRNAs covering the fusion point of TCF3-PBX1 was evaluated in 697 cells in vitro. Anti-TCF3-PBX1 siRNA3 was most effective (87% knockdown) and was used for all further experiments (Supplemental Figure S2). The delivery efficiency at various concentrations (0.25-2μg/ml) of LNP-siRNA formulations in 697 cells was 100% even at the lowest concentration (Figure 1A). The LNP-TCF3-PBX1 siRNA efficiency in 697 cells was confirmed by RT-PCR showing a knockdown of TCF3-PBX1 expression up to 80% at higher and 65-70% at lower concentrations compared to LNP-CTRL siRNA at 72 hours (Figure 1B). Also, we detected a robust knockdown of the TCF3-PBX1 protein as shown by Western blot at 72 hours in 697 cells treated with LNP-siRNA (CTRL or TCF3-PBX1, Supplemental Figure S3A). 697 cells underwent cell death in a concentration dependent manner when treated with LNP-TCF3-PBX1 siRNA but not with LNP-CTRL siRNA (Figure 1C). Consistently, we observed a significant increase in apoptotic Annexin V positive cells treated with LNP-TCF3-PBX1 siRNA compared to LNP-
CTRL siRNA (Supplemental Figure S3B). To confirm the specific nature of TCF3-PBX1 siRNA, we also treated the K562 cell line with LNP-TCF3-PBX1 siRNA formulations and did not observe any significant non-specific effects on cell viability and apoptosis (Supplemental Figure S4A-B). Moreover, no significant decrease in expression levels of TCF3 and PBX1 mRNA levels in K562 cells were observed (Supplemental Figures S4C-D).

To evaluate the LNP-siRNA uptake in difficult to transfect human patient derived cells, we incubated the LNP-CTRL siRNA formulation with freshly isolated leukemic cells from patients with CML and ALL in cytokine supplemented primary human cell culture media. We observed an efficient dose dependent uptake of LNP-CTRL siRNA in the CD34 positive population and with variable efficacy in CD34 negative primary cells from these patients at 72 hours after a single treatment (Supplemental Figure S5A-B). These data show that our LNPs are efficiently taken up under normal growth conditions even in difficult to transfect primary myeloid and lymphoid leukemic cells. In order to confirm the internalization of LNP-siRNA, we performed confocal microscopy in primary cells of a patient with acute myeloid leukemia after treatment with 1μg/ml of LNP-CTRL siRNA or LNP-fluorescein isothiocyanate (FiTC) tagged-CTRL siRNA. We quantified the confocal images and found that all cells treated with LNP-FiTC tagged siRNA showed cytoplasmic uptake of the siRNAs (Supplemental Figure S5C for confocal images and Figure S5D for quantification of the FiTC signal).

We next assessed the delivery potential and efficacy of our LNPs in vivo, with a focus on hematopoietic tissues following systemic administration. Female 6-8 week old Nod-Scid-IL2Rgamma<sup>–/–</sup> (NSG) mice transplanted intrafemorally with K562 leukemia cells received 3 injections of LNP-CTRL siRNA at different doses (1 or 5 mg/kg body weight) and routes of administration (intravenously (i.v.) or intraperitoneally (i.p.)). The 3 injections were applied at 0, 8 and 24 hours starting 10 days after transplantation, and mice were analyzed at 48 hours. Importantly, 89-95% of human K562 cells had taken up LNPs in myelosarcoma tissue and 67-99% in murine cells from different organs (peripheral blood, bone marrow, spleen, liver) independent of the routes of administration (Supplemental Figure S6). The percentage of LNP positive cells was significantly lower in all organs except myelosarcoma tissue at a dose of 1 mg/kg compared to a dose of 5 mg/kg (Supplemental Figure S6).

To evaluate our technology in primary patient cells in vivo, we transplanted cells from the TCF3-PBX1 positive B-ALL patient in sub-lethally irradiated NSG mice. We treated the TCF3-PBX1 dependent B-ALL PDX mice with 10 injections of 2.5mg/kg LNP-CTRL siRNA or LNP-TCF3-PBX1 siRNA, starting from day 7 after transplantation over a period of 24 days. The majority of human (and mouse) cells in the bone marrow of treated mice showed uptake of LNPs at death (48 hours after the last injection, Supplemental Figure S7A). We observed a 55% knockdown of TCF3-PBX1 mRNA levels in spleen cells from moribund mice treated with 10 injections of LNP-TCF3-PBX1 siRNA compared to LNP-CTRL siRNA (Figure 2A). The leukemia development in mice was monitored by quantifying the percentage of CD45+ transplanted human leukemia cells in peripheral blood. A delayed onset of leukemia and significantly lower engraftment of CD45+ cells were observed in mice treated with LNP-TCF3-PBX1 siRNA compared to mice treated with LNP-CTRL siRNA (Figure 2B). Importantly, mice treated with LNP-TCF3-PBX1 siRNA showed...
survived significantly longer compared to LNP-CTRL siRNA treated mice (median OS 45 days vs 32 days, P=0.0026, Figure 2C). At day 33, white blood cell counts (WBC) were significantly lower and higher platelet counts were observed in LNP-TCF3-PBX1 siRNA treated mice (Supplemental Figures S7B-C). In the bone marrow of moribund mice treated with LNP-TCF3-PBX1 siRNA, we found a lower proportion of blast cells than in LNP-CTRL siRNA treated mice (Supplemental Figures S7D and S7E). By targeting the TCF3-PBX1 fusion oncogene we show a reduction of leukemic burden in our patient derived lymphoblastic leukemia xenotransplant mouse model, and demonstrate improved survival of PDX mice treated with LNP-TCF3-PBX1 siRNA as compared to LNP-CTRL siRNA.

It has been shown that the intracellular uptake of our nanoparticles is dependent on the association with ApoE and binding to the low density lipoprotein receptor (LDL). The LDL receptor is widely expressed on leukemic cells and was also expressed in our TCF3-PBX1 positive leukemia cells (Supplemental Figure S8A-B). So far, no cellular ligand has been identified that is selectively expressed on leukemic but not on normal stem cells. Effective inhibition of cyclin D1 in a mantle cell lymphoma mouse model using αCD38 antibody-LNPs encapsulating CycD1 siRNA was recently reported by Peer et al. However, conjugating a targeting ligand to delivery systems may result in physicochemical instability in blood circulation and decreased accumulation at target tissues. Thus, the use of a leukemia-specific siRNA enabled us to abstain from a targeted delivery approach. In summary, we have developed LNP-siRNA formulations that target primary human leukemia cells in vitro and in vivo with high efficacy, deliver a leukemia-specific siRNA to leukemic cells and thus prolong survival of mice bearing a patient derived TCF3-PBX1 positive ALL. Fusion oncogenes thus represent disease specific targets for RNAi and should be exploited to realize a new mode of personalized treatment in leukemia patients.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank Silke Glowotz, Martin Wichmann, Anitha Thomas and Colin Walsh for technical support. We express sincere thanks to the patients for their participation in the study. We thank Prof. Dr. Alf Lamprecht and Dr. Manusnrit Singh for providing us nanoparticles during the initial experiments. We thank the staff of the Central Animal Facility and Matthias Ballmaier from the Cell Sorting Core Facility (supported in part by the Braukmann-Wittenberg-Herz-Stiftung and the Deutsche Forschungsgemeinschaft) of Hannover Medical School. This study was supported by the Rudolf-Bartling Stiftung, an ERC grant under the European Union’s Horizon 2020 research and innovation programme (No. 638035), by grants 110284, 110287, 110292 and 111267 from Deutsche Krebshilfe; grant DICLS R13/14 from the Deutsche José Carreras Leukämie-Stiftung e.V; the German Federal Ministry of Education and Research grant 01EO0802 (IFB-Tx); DFG grant HE 5240/5-1, HE 5240/5-2 and HE 5240/6-1; grants from Dieter-Schlag Stiftung and a Terry Fox Foundation Program Project Award to RKH.

References

1. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013 Aug 29; 369(9):819–829. [PubMed: 23984729]
2. Fitzgerald K, Kallend D, Simon A. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. N Engl J Med. 2017 May 04.376(18):e38.
3. Rungta RL, Choi HB, Lin PJ, Ko RW, Ashby D, Nair J, et al. Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain. Mol Ther Nucleic Acids. 2013 Dec 03;2:e136. [PubMed: 24301867]

4. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007 Apr; 7(4):233–245. [PubMed: 17361217]

5. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015 Oct 15; 373(16):1541–1552. [PubMed: 26465987]

6. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MO, et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther. 2006 Oct; 14(4): 476–484. [PubMed: 16829204]

7. Fleischmann KK, Pagel P, Schmid I, Roscher AA. RNAi-mediated silencing of MLL-AF9 reveals leukemia-associated downstream targets and processes. Mol Cancer. 2014 Feb 11.13:27. [PubMed: 24517546]

8. Takenaka S, Naka N, Araki N, Hashimoto N, Ueda T, Yoshioka K, et al. Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo. Int J Oncol. 2010 Apr; 36(4):823–831. [PubMed: 20198325]

9. Urbinati G, Ali HM, Rousseau Q, Chapuis H, Desmaele D, Couvreur P, et al. Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer. PLoS One. 2015; 10(5):e0125277. [PubMed: 25933120]

10. Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med. 2007 Jun; 7(2):47–55. [PubMed: 17609876]

11. Heim, S., M, F. Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells. 4th edn. Wiley-Blackwell; 2015.

12. Felice MS, Gallego MS, Alonso CN, Alfaro EM, Guitter MR, Bernasconi AR, et al. Prognostic impact of t(1;19)/ TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Munster-based protocols. Leuk Lymphoma. 2011 Jul; 52(7):1215–1221. [PubMed: 21534874]

13. Fischer U, Forster M, Rinaldi A, Risch T, Sungalee S, Warnatz HJ, et al. Genomics and drug profiling of fatal TCF3-MLL-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet. 2015 Sep; 47(9):1020–1029. [PubMed: 26214592]

14. Weinstein S, Toker IA, Emmanuel R, Ramishetti S, Hazan-Halevy I, Rosenblum D, et al. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proc Natl Acad Sci U S A. 2016 Jan 05; 113(1):E16–22. [PubMed: 26699502]

15. Jin SE, Jin HE, Hong SS. Targeted delivery system of nanobiomaterials in anticancer therapy: from cells to clinics. Biomed Res Int. 2014; 2014 814208.
Figure 1. Uptake and on-target efficacy of LNP-siRNA formulations in TCF3-PBX1 expressing 697 human B-ALL leukemia cells in vitro.

A. Representative FACS plot showing the percentage of Dil (LNP) positive cells as measured by flow cytometry in TCF3-PBX1 expressing 697 cells treated with LNP-TCF3-PBX1 siRNA (0.25, 0.5, 1 and 2 µg/ml siRNA, corresponding to 17.85, 35.7, 71.43, and 143 nM siRNA, respectively) after 72 hours. The concentrations in µg/ml refer to the siRNA concentration.

B. RT-PCR validation of TCF3-PBX1 knockdown in the TCF3-PBX1 positive 697 cell line in vitro using LNP encapsulated TCF3-PBX1 siRNA or LNP-CTRL siRNA after 72 hours of treatment (mean ± SEM, n=3).

C. Viability of 697 cells treated in vitro with LNP-CTRL or LNP-TCF3-PBX1 siRNA for 6 days at the indicated concentrations (mean ± SEM, n=6).

** indicates P<.01.
Figure 2. TCF3-PBX1 siRNA can be efficiently delivered in patient derived human acute lymphoblastic leukemia cells in vivo in a xenograft mouse model and prolongs survival of mice. A. Knockdown of TCF3-PBX1 in spleen cells of TCF3-PBX1 expressing ALL-PDX mice treated with LNP-siRNA (CTRL or TCF3-PBX1). LNP-siRNA formulations (2.5mg/kg) were injected intraperitoneally 10 times (days 7, 8, 13, 15, 19, 20, 22, 23, 29 and 30, considering the transplantation date as day 0) (mean ± SEM, n=3). B. Engraftment of human CD45 positive primary ALL cells at different time points in peripheral blood (PB) of TCF3-PBX1 expressing ALL-PDX mice treated with LNP-siRNA (CTRL or TCF3-PBX1, n=5 each). LNP-siRNA formulations (2.5mg/kg) were injected 10 times (days 7, 8, 13, 15, 19, 20, 22, 23, 29 and 30, considering the transplantation date as day 0). C. Survival of ALL-PDX mice treated with LNP-siRNA (CTRL or TCF3-PBX1). LNP-siRNA formulations (2.5mg/kg) were injected 10 times (days 7, 8, 13, 15, 19, 20, 22, 23, 29 and 30, considering the transplantation date as day 0; n=5 per group). * indicates P<.05, ** indicates P<.01, ns, not significant.